content: SECURITIES AND EXCHANGE             
                            COMMISSION
                      Washington, D.C.  20549
       
       
       
       
       
                        FORM 8-K
       
       
       
                     CURRENT REPORT
       
            Pursuant to Section 13 or 15(d) of the        
               Securities Exchange Act of 1934
       
           Date of Report (date of earliest event           
                reported):  February 22, 1995
       
       
                MOLECULAR BIOSYSTEMS, INC.
       (Exact name of registrant as specified in its      
                        charter)
       
       
       
       Delaware          0-12648      36-30878632
       (State or other  (Commission   (IRS  employer
       jurisdiction of  file number)  identification      
       incorporation)                  number)
       
       
                  10030 Barnes Canyon Road, 
                San Diego, California  92121
              (Address of principal executive             
                       offices)
       
           
       Registrant's telephone number, including 
              area code:   (619) 452-0681
       
       
       
       
       
       Item 5.   Other Events.
       
       
       On February 22, 1995, Molecular Biosystems, Inc.
       (the "Company") announced that it intended to
       focus future research and development activities
       exclusively on the Company's contrast agents for
       ultrasound imaging.
       
       The Company's contrast agents for ultrasound
       imaging include:  ALBUNEX(R), the first
       commercially-available contrast agent for
       transpulmonary cardiac ultrasound imaging, which
       the U.S. Food and Drug Administration (the "FDA")
       approved for sale in August 1994; ORALEX(TM), a
       contrast agent for ultrasound imaging of the
       gastrointestinal tract and surrounding organs,
       which is currently undergoing Phase I clinical
       trials; and FS069, the Company's second-generation
       cardiac contrast agent, which is intended to
       permit ultrasound imaging of myocardial perfusion
       and for which the Company is currently awaiting
       approval from the FDA to begin Phase I clinical
       trials.
       
       In connection with this narrowing of the Company's
       research and development focus, the Company
       reduced the number of its employees by 48, from a
       total of 197 employees to a total of 149
       employees.
       
       The Company anticipates that as a result of these
       changes, the Company will reduce its expenses by
       approximately $6 million annually.
       
       A copy of the press release that the Company
       issued on February 22, 1995, to announce these
       changes is attached to this Report as Exhibit
       10.1.
       
       
       
       
       
       
       
       
   
  
  
  
  
  
  
  
        
  
  
  
  
  
  
  
  
                      Signatures
                                  
       
       
       Pursuant to the requirements of the Securities
       Exchange Act of 1934, the registrant has duly
       caused this report to be signed on its behalf by
       the undersigned hereunto duly authorized.
       
       Date:  March 6, 1995
       
       
                        MOLECULAR BIOSYSTEMS, INC.
       
       
       
                        By:s/STEVEN LAWSON
                        _________________________
                        Steven Lawson
                        Vice President,
                        Legal Affairs and 
                        General Counsel
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
       
       
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
                   Exhibit Index
                                  
       
       
                                                               
                                      Sequentially
                                        Numbered
       Exhibit     Description            Page
       10.1       Press release             5
                (February 22, 1995)
metadata_documents: [{"type": "8-K", "sequence": "1", "secsgml_size_bytes": 3825}]
metadata_filer: {"company-data": {"conformed-name": "MOLECULAR BIOSYSTEMS INC", "cik": "0000719598", "assigned-sic": "2835", "irs-number": "363078632", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-12648", "film-number": "95518880"}, "business-address": {"street1": "10030 BARNES CANYON RD", "city": "SAN DIEGO", "state": "CA", "zip": "92121-2789", "phone": "6194520681"}, "mail-address": {"street1": "10030 BARNES CANYON ROAD", "city": "SAN DIEGO", "state": "CA", "zip": "92121"}}
text: SECURITIES AND EXCHANGE             
                            COMMISSION
                      Washington, D.C.  20549
       
       
       
       
       
                        FORM 8-K
       
       
       
                     CURRENT REPORT
       
            Pursuant to Section 13 or 15(d) of the        
               Securities Exchange Act of 1934
       
           Date of Report (date of earliest event           
                reported):  February 22, 1995
       
       
                MOLECULAR BIOSYSTEMS, INC.
       (Exact name of registrant as specified in its      
                        charter)
       
       
       
       Delaware          0-12648      36-30878632
       (State or other  (Commission   (IRS  employer
       jurisdiction of  file number)  identification      
       incorporation)                  number)
       
       
                  10030 Barnes Canyon Road, 
                San Diego, California  92121
              (Address of principal executive             
                       offices)
       
           
       Registrant's telephone number, including 
              area code:   (619) 452-0681
       
       
       
       
       
       Item 5.   Other Events.
       
       
       On February 22, 1995, Molecular Biosystems, Inc.
       (the "Company") announced that it intended to
       focus future research and development activities
       exclusively on the Company's contrast agents for
       ultrasound imaging.
       
       The Company's contrast agents for ultrasound
       imaging include:  ALBUNEX(R), the first
       commercially-available contrast agent for
       transpulmonary cardiac ultrasound imaging, which
       the U.S. Food and Drug Administration (the "FDA")
       approved for sale in August 1994; ORALEX(TM), a
       contrast agent for ultrasound imaging of the
       gastrointestinal tract and surrounding organs,
       which is currently undergoing Phase I clinical
       trials; and FS069, the Company's second-generation
       cardiac contrast agent, which is intended to
       permit ultrasound imaging of myocardial perfusion
       and for which the Company is currently awaiting
       approval from the FDA to begin Phase I clinical
       trials.
       
       In connection with this narrowing of the Company's
       research and development focus, the Company
       reduced the number of its employees by 48, from a
       total of 197 employees to a total of 149
       employees.
       
       The Company anticipates that as a result of these
       changes, the Company will reduce its expenses by
       approximately $6 million annually.
       
       A copy of the press release that the Company
       issued on February 22, 1995, to announce these
       changes is attached to this Report as Exhibit
       10.1.
       
       
       
       
       
       
       
       
   
  
        
  
                      Signatures
                                  
       
       
       Pursuant to the requirements of the Securities
       Exchange Act of 1934, the registrant has duly
       caused this report to be signed on its behalf by
       the undersigned hereunto duly authorized.
       
       Date:  March 6, 1995
       
       
                        MOLECULAR BIOSYSTEMS, INC.
       
       
       
                        By:s/STEVEN LAWSON
                        _________________________
                        Steven Lawson
                        Vice President,
                        Legal Affairs and 
                        General Counsel
  
       
       
  
                   Exhibit Index
                                  
       
       
                                                               
                                      Sequentially
                                        Numbered
       Exhibit     Description            Page
       10.1       Press release             5
                (February 22, 1995)